Rectal nitric oxide as biomarker in the treatment of inflammatory bowel disease: Responders versus nonresponders

Figure 1 A: Rectal NO levels in UC; B: Rectal NO levels in CD.

Figure 2 Rectal NO levels in the treatment of UC and CD patients on d 1. ^bP < 0.001 vs Control; ^dP < 0.01, ^aP < 0.05 vs patients responding to treatment.

Figure 3 Correlation between mucosal iNOS-expressing cells and rectal NO levels in patients with UC.

Figure 4 A Colonic histology of CD patients (A, C, E, G) before and (B, D, F, G) after treatment on d 28. Antibodies against iNOS (A, B), TNF-α (C, D), IL-1β (E, F) and INF-γ (G, H); Colonic histology of healthy control. Antibodies against iNOS (I), TNF-α (J), IL-1β (K) and INF-γ (L).

Figure 5 A: Semi-quantitative PCR iNOS gene of cDNA from non-inflamed (lanes 1-6), and inflamed (lanes 7-12) colon biopsies from a patient with ulcerative colitis; B: Difference in semi-quantitative PCR iNOS gene expression.